SEC Company Response from Addex Therapeutics Ltd. (ADXN) (CIK 0001574232) (ADXN) — Jan 23, 2020
Addex Therapeutics Ltd. (ADXN) (CIK 0001574232)
Date: Jan. 23, 2020 · CIK: 0001574232 · Accession: 0001104659-20-006230
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235554
Letter
Addex Therapeutics Ltd
Chemin Des Mines 9
CH 1202 Geneva, Switzerland
VIA EDGAR
January 23, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ada D. Sarmento
Mary Beth Breslin
Re: Addex Therapeutics Ltd
Acceleration Request for Registration Statement on Form F-1
File No. 333-235554
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Addex Therapeutics Ltd (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 27, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Cooley LLP, by calling Joshua A. Kaufman at (212) 479-6495.
If you have any questions regarding this request, please contact Joshua A. Kaufman of Cooley LLP at (212) 479-6495. Thank you for your assistance with this matter.
Sincerely,
ADDEX THERAPEUTICS LTD
Show Raw Text
CORRESP 1 filename1.htm Addex Therapeutics Ltd Chemin Des Mines 9 CH 1202 Geneva, Switzerland VIA EDGAR January 23, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento Mary Beth Breslin Re: Addex Therapeutics Ltd Acceleration Request for Registration Statement on Form F-1 File No. 333-235554 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Addex Therapeutics Ltd (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 27, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Cooley LLP, by calling Joshua A. Kaufman at (212) 479-6495. If you have any questions regarding this request, please contact Joshua A. Kaufman of Cooley LLP at (212) 479-6495. Thank you for your assistance with this matter. Sincerely, ADDEX THERAPEUTICS LTD /s/ Tim Dyer Tim Dyer Chief Executive Officer